A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries
about
Unresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritisRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesAssociation of rheumatoid arthritis susceptibility gene with lipid profiles in patients with rheumatoid arthritisCardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritisFolic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritisBiologics registers in RA: methodological aspects, current role and future applications.Identifying newly approved medications in Medicare claims data: a case study using tocilizumab.Use of health plan combined with registry data to predict clinical trial recruitment.Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries.Associations of smoking and alcohol consumption with disease activity and functional status in rheumatoid arthritis.Effectiveness and Costs of TNF-Alpha Blocker Use for Patients with Rheumatoid ArthritisA window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice?Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.Malignancy validation in a United States registry of rheumatoid arthritis patients.The incidence of gastrointestinal perforations among rheumatoid arthritis patients.The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology networkThe comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agentsValidation of Diagnostic and Procedural Codes for Identification of Acute Cardiovascular Events in US Veterans with Rheumatoid Arthritis.Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.Comparative effectiveness and safety of rituximab versus subsequent anti-tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti-tumor necrosis factor therapies in the United States Corrona registry.Physicians' explanations for apparent gaps in the quality of rheumatology care: results from the US Medicare Physician Quality Reporting System.The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countriesBody mass index and the rheumatoid arthritis swollen joint count: an observational study.Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis.Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.Appearance of ANCA - associated vasculitis under Tumor necrosis factor-alpha inhibitors treatment.Predictors of longterm changes in body mass index in rheumatoid arthritis.Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis.Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study.Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany.Risk of orthopedic surgical site infections in patients with rheumatoid arthritis treated with antitumor necrosis factor alfa therapy.The importance of rheumatology biologic registries in Latin America.Comparison of characteristics of international and national databases for rheumatoid arthritis: a systematic literature review.Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review.Biosimilars in rheumatology: current perspectives and lessons learnt.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Modeling of the clinical and economic impact of a risk-sharing agreement supporting a treat-to-target strategy in the management of patients with rheumatoid arthritis in France.
P2860
Q26822912-54C3A745-A2B4-4668-BABF-2C24A9CF90CCQ26991673-2A62A4A6-F42C-405B-9C0E-0201851EF803Q28386085-69F705D0-35DD-4847-B789-FB972A1697C6Q28390163-8793F7C4-499E-46FB-8F56-12705E982C49Q28394552-CA1FF279-BAD5-4BBE-A948-E38CB277CA6CQ30234303-92405B4E-462A-4886-A545-79FB93480D7FQ30667044-E1F94E09-09CD-447B-A06D-4B643EF5450AQ30717256-C9EB543F-8D4A-493E-BE8B-31E15C2E9C8CQ30891297-FD168890-4CF7-4082-BF42-49BED80575C8Q33596873-8F8DC4A2-41A7-4463-BFC3-BAD47CEFA123Q33652800-237C449F-9C7A-4E0F-8E59-9B810D6EB9E3Q33840415-A554B7FE-ECFE-490D-93F4-0788F46005A7Q34076916-31AE2E34-B7C1-4B81-8D70-EFFF4B936035Q34287960-6EDB4F46-407D-4321-93C6-1D12FAD5C3B6Q34543316-A06CAE9F-9D1E-4E2E-95A7-25776F01FAF8Q34643212-CA0E2A51-E539-4D79-8B75-5D6E097DA531Q35082559-9960CE60-802A-4A37-A0FD-DF823B0C6FC6Q35211291-CF06CD5B-2511-48CD-A29F-FED2362464C8Q35840753-A5A81790-F6BB-4EC8-BAD5-092D0E0489B8Q36071720-BD19D04A-FE60-4D69-8442-0FB99C12DA17Q36150089-EE182A5F-7008-4F78-80C4-5C881000C4D6Q36183803-AC881CDB-E2F0-4119-ABC0-19E00BEADB7FQ36198718-FF82B420-D7EE-4235-87D5-8C578335A97DQ36216285-E23C3140-5CAB-431C-ABF3-774332C7946CQ36677345-0779B0EF-6BF0-467A-81AB-3D4A9AAB7450Q36746668-88BC449F-1F2D-4F92-8C0A-6A76D24C34BEQ36784187-5311164E-2471-4ADF-A783-70D228B4FD7FQ36784192-1AD93F0F-EC68-4F8E-9B4C-11AA910E0BBEQ36942914-EF10677A-7894-4304-BA98-DD897F37FCAFQ37051820-119E9E15-2A45-452B-8F26-7CFC22DD6F10Q37309669-906DB8F7-FE65-48E3-9570-42ABFEE4A736Q37330765-A8CEDD12-50CF-46FF-AB39-A3CF899FDA7DQ37452672-8E737EBE-FD3E-4072-9260-D05D8D73F3D2Q38002409-F16A973D-B1A5-43EF-B2F7-B9706CB045F1Q38069473-AB66234D-04A1-4B79-B00D-1CB7EB093045Q38217664-BF857338-516A-436F-B28D-F7E815B0C679Q38338700-A9C36F14-8B0A-421E-97FB-D9E3A726059AQ38568463-626F23AF-A225-4E7C-8FC5-5F254A35224CQ38755133-29CDA053-BCEF-41BF-9EC4-A5C4232DCC76Q38804610-7A3C585C-22D4-4407-B961-A87CB4EBEF62
P2860
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A comparison of patient charac ...... heumatoid arthritis registries
@ast
A comparison of patient charac ...... heumatoid arthritis registries
@en
A comparison of patient charac ...... heumatoid arthritis registries
@nl
type
label
A comparison of patient charac ...... heumatoid arthritis registries
@ast
A comparison of patient charac ...... heumatoid arthritis registries
@en
A comparison of patient charac ...... heumatoid arthritis registries
@nl
prefLabel
A comparison of patient charac ...... heumatoid arthritis registries
@ast
A comparison of patient charac ...... heumatoid arthritis registries
@en
A comparison of patient charac ...... heumatoid arthritis registries
@nl
P2093
P2860
P50
P1476
A comparison of patient charac ...... heumatoid arthritis registries
@en
P2093
Angela Zink
Archana Jain
Daniel H Solomon
Fred Wolfe
Jeffrey D Greenberg
Jeffrey R Curtis
Joachim Listing
Joel Kremer
Johan Askling
Kaleb Michaud
P2860
P304
P356
10.1016/J.SEMARTHRIT.2010.03.003
P577
2010-08-01T00:00:00Z